Home › Trial NCT07187960
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
- Trial IDNCT07187960
- StatusNot Yet Recruiting
- PhasePhase 3
- Study typeInterventional
- SponsorShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Enrollment228
- Start date2025-11
- ConditionsFollicular Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.